IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

Institute for Quality and Efficiency in Health Care

Programme
IQWiG in Dialogue
21 June 2013

„Importance of approval status for the benefit assessment“

Presentation: Professor Dr Ralf Bender

10.00 - 10.10	**Introduction to the topic** Dr Beate Wieseler, IQWiG
10.10 - 10.30	**Criteria for checking the applicability of study results** PD Dr Ulrich Grouven, IQWiG
10.30 - 11.00	**Approval studies and therapeutic indication - experience from the early benefit assessment** Dr Thomas Kaiser, IQWiG
11.00 - 12.00	**Discussion**
12.00 - 13.00	**Lunch break**
13.00 - 13.30	**From clinical data to therapeutic indication – a compass for the benefit assessment?** Dr Karl Broich, Federal Institute for Drugs and Medical Devices, Bonn
13.30 - 14.00	**New drugs between approval and benefit assessment – how do manufacturers manage?** Professor Dr Torsten Strohmeyer, GlaxoSmithKline, Munich
14.00 - 14.30	**Importance of approval status for G-BA decisions** Max Grüne, Federal Joint Committee, Berlin
14.30 - 15.30	**Discussion**
15.30 - 16.00	**Conclusion of the event with coffee and biscuits**

Venue: KOMED, Im Mediapark 6, 50670 Cologne